Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 May;33(5):1873-9.

Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells.

Author information

1
Department of Medical Microbiology and Immunology, Creighton University Medical School, Criss III, Room 352, 2500 California Plaza, Omaha, NE 68178, USA.

Abstract

Accumulating experimental and clinical evidence has indicated that tumor-initiating or cancer stem-like cells are a sub-population of tumor cells capable of initiating and driving tumor growth, and cancer stem-like cells are resistant to most current cancer therapies, including chemo- and radiation therapy. More effective targeted-therapeutic approaches are urgently needed to eliminate cancer stem-like cells. Here, we report that broussoflavonol B, a chemical purified from the bark of the Paper Mulberry tree (broussonetia papyrifera), exhibited potent growth inhibitory activity towards estrogen receptor (ER)-negative breast cancer SK-BR-3 cells at sub-micromolar concentrations. Broussoflavonol B more potently inhibited growth and induced differentiation of stem-like SK-BR-3 cells-compared to the anti-estrogen tamoxifen. In addition, broussoflavonol B treatment also reduced the steady, state levels of the Human epidermal growth factor receptor-2 (HER2) and ER-α36, a variant of ER-α. Our results, thus, indicate that broussoflavonol B is a potent growth inhibitor of ER-negative breast cancer stem-like cells and provide a rationale for pre-clinical and clinical evaluation of broussoflavonol B for breast cancer therapy.

KEYWORDS:

Broussoflavonol B; cancer stem-like cells; estrogen receptor

PMID:
23645733
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center